Page 2 - Cipla Technologies News Today

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) and Pulmatrix (NASDAQ:PULM – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Valuation and Earnings This table compares Rocket Pharmaceuticals and Pulmatrix’s […]

Increasing Awareness of Healthcare Among Population Are Likely To Aid the Market Growth of the Bronchodilators Market.

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b data anticipated in Q4 2021 Phase 1/ Phase 2 Study for PUR3100 in acute migraine treatment on-track for study start in Q1 2022 Cash runway extends beyond anticipated PUR1800 Ph1b and PUR3100 Ph1/Ph2 data milestones Pulmatrix seeks reaffirmation of 50/50 partnership from Cipla Technologies News provided by Share this article Share this article LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulma...